Arcturus Therapeutics reported Q4 FY2025 total revenue of USD 7.2 million (down 68.4%), including collaboration revenue of USD 3.1 million (down 85.3%) and grant revenue of USD 4.1 million (up 133%). Q4 operating expenses were USD 38.5 million (down 31.5%), with R&D expense of USD 24.5 million (down 44.1%) and G&A expense of USD 14.0 million (up 13.3%). Q4 net loss was USD 29.1 million, or USD (1.03) per diluted share. For FY2025, Arcturus Therapeutics posted total revenue of USD 82.0 million (down 46.2%), operating expenses of USD 158.3 million (down 36.2%), and a net loss of USD 65.8 million, or USD (2.40) per diluted share. Cash, cash equivalents and restricted cash totaled USD 232.8 million as of December 31, 2025, and the company said its cash runway is extended into Q2 2028. On the pipeline, Arcturus Therapeutics said ARCT-032 (once-daily inhaled mRNA for cystic fibrosis) completed 28 days of dosing at 15 mg in the Phase 2 third cohort and was generally safe and well tolerated; the safety review committee allowed the program to proceed into a 12-week Phase 2 study expected to begin dosing in H1 2026. The company also said it is broadening development strategy for ARCT-810 in ornithine transcarbamylase deficiency, with Type C regulatory meetings on track for H1 2026. Arcturus Therapeutics noted the UK MHRA approved its self-amplifying mRNA COVID-19 vaccine KOSTAIVE in January 2026 for adults 18 and older, and highlighted durable immune-response data for its self-amplifying mRNA pandemic influenza (A/H5N1) vaccine under a BARDA contract.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603031601BIZWIRE_USPR_____20260303_BW197744) on March 03, 2026, and is solely responsible for the information contained therein.
Comments